Human trials for world’s first AI-designed immuno-oncology drug
The drug was discovered through an AI-design platform within just eight months of project initiation
Read More
Tag: Phase I
Positive Phase I results for Allergy’s Acarovac
Good news for patients with house dust mite-induced allergic rhinoconjunctivitis.
Read More
Merck drug shows promise in Alzheimer’s disease
Merck & Co’s BACE1 inhibitor verubecestat has shown promise in a Phase I trial assessing its potential in Alzheimer’s disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
